CRX100
Cell therapy
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Colorectal Cancer · Phase 1Hepatocellular Carcinoma · Phase 1Ovarian Cancer · Phase 1Gastric Cancer · Phase 1Melanoma · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04282044 NCT04282044 · Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma Registry: NCT04282044 | 1 | Frequency of treatment-emergent Adverse Events and Dose Limiting Toxicities (28 days following dose administration for each dosed subject.); Determine the maximum tolerated dose (MTD), maximum feasible dose (MFD) or optimal biological dose (OBD) and determine recommended Phase 1b/Phase 2a dose level. (28 days following dose administration for each dosed subject.) 2025-08 | In progress: primary completion was expected 1 Aug 2025; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Colorectal Cancer: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CRX100: this drug | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Encorafenib | Approved | Small molecule | BRAF V600E | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Approved | Small molecule | VEGFR1/2/3 | Reliable signal | NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis) | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016) | |
| Sotorasib | Approved | Small molecule | KRAS G12C | not yet graded | No reviewed efficacy summary in this indication | |
| Tucatinib | Approved | Small molecule | HER2 | Partial signal | NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| Becotatug | Phase 3 | Monoclonal antibody | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| Botensilimab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| HLX04 (Hanbeitai) | Phase 3 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| IBI363 | Phase 3 | Multispecific antibody | PD-1 x IL-2Rα (IL2RA) | not yet graded | No reviewed efficacy summary in this indication | |
| INCA33890 | Phase 3 | Multispecific antibody | TGF-βR2 and PD-1 (conditional bispecific) | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| S-1 | Phase 3 | Small molecule | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil) | not yet graded | No reviewed efficacy summary in this indication | |
| Telisotuzumab Adizutecan | Phase 3 | Antibody–drug conjugate | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| N-Dihydrogalactochitosan | Phase 2/3 | Polysaccharide | STING and inflammasome pathways | not yet graded | No reviewed efficacy summary in this indication | |
| DSP107 | Phase 2 | Protein / enzyme therapeutic | SIRP-alpha/4-1BBL fusion protein | not yet graded | No reviewed efficacy summary in this indication | |
| IBI305 | Phase 2 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Sirexatamab | Phase 2 | Monoclonal antibody | DKK1 (Dickkopf-1) | not yet graded | No reviewed efficacy summary in this indication | |
| A2B530 | Phase 1/2 | Cell therapy | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker) | not yet graded | No reviewed efficacy summary in this indication | |
| NC410 | Phase 1/2(overall) | Protein / enzyme therapeutic | Collagen (LAIR-1 ligands) | not yet graded | No reviewed efficacy summary in this indication | |
| BBO-10203 | Phase 1 | Small molecule | RAS:PI3Kα protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| KRAS-Specific Autologous TCR-T Cell | Phase 1(overall) | Cell therapy | KRAS G12V presented on HLA-A*11:01 | not yet graded | No reviewed efficacy summary in this indication | |
| LY01008 | Phase 1 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Palupiprant | Phase 1 | Small molecule | EP4 | Weak signal | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Tusamitamab Sonditecan | Phase 1 | Antibody–drug conjugate | CEACAM5 | not yet graded | No reviewed efficacy summary in this indication | |
| PI3Kalpha Precision Therapy | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.